{"blog": [], "keywords": [{"value": "Roche Holding AG", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Bladder Cancer", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "4", "is_major": "Y"}, {"value": "Immune System", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/05/19/business/food-and-drug-administration-immunotherapy-bladder-cancer.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbWide.jpg", "legacy": {"wide": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-articleLarge.jpg", "legacy": {"xlarge": "images/2016/05/19/business/19IMMUNE/19IMMUNE-articleLarge.jpg", "xlargeheight": "961", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 961}, {"url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1008", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The drug, Tecentriq from Roche, works by using the body\u2019s immune system against tumors, and is the first drug of its type approved for bladder cancer.", "pub_date": "2016-05-19T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "F.D.A. Approves Immunotherapy Drug for Treatment of Bladder Cancer", "main": "F.D.A. Approves an Immunotherapy Drug for Bladder Cancer"}, "print_page": "3", "snippet": "The drug, Tecentriq from Roche, works by using the body\u2019s immune system against tumors, and is the first drug of its type approved for bladder cancer.", "_id": "573ccd9338f0d81236fa7ee1", "slideshow_credits": null, "abstract": "Food and Drug Administration approves Roche's new immunotherapy drug, Tecentriq, to treat bladder cancer; drug belongs to class of medicines called checkpoint inhibitors."}